FDA’s Drug Price Push in Biosimilar Plan Hinges on Other Reforms
Hatch-Waxman & Biologics Chair Chad Landmon explains that although the FDA is speeding up approvals of cheaper biosimilars, barriers such as patents, insurance practices and PBM policies still keep these lower-cost options from reaching patients and lowering prices.